Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.22
+0.04 (3.31%)
Market open: Aug 12, 2026, 11:10 AM EDT
1.17
-0.01 (-0.84%)
Previous after-hours: Aug 11, 2026, 7:42 PM EDT
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
| Name | Position |
|---|---|
| Dr. Andrew Fang Ph.D. | Head of Business Development |
| Date | Type | Document |
|---|---|---|
| 2026-07-28 | 8-K | d105624d8k.htm |
| 2026-07-22 | 8-K | d107304d8k.htm |
| 2026-07-17 | DEF 14A | ny20077454x2_def14a.htm |
| 2026-07-07 | PRE 14A | ny20077454x1_pre14a.htm |
| 2026-06-26 | S-3 | d135184ds3.htm |
| 2026-06-23 | D | |
| 2026-06-23 | 8-K | d158247d8k.htm |
| 2026-06-08 | DEF 14A | ny20072803x2_def14a.htm |
| 2026-06-04 | 8-K | d91703d8k.htm |
| 2026-06-02 | 8-K | d105562d8k.htm |